Minimize tax risk, maximize tax opportunities in transactions.
A&M’s Tax Corporate Due Diligence services team is comprised of seasoned experts that are knowledgeable in all tax due diligence matters. Whether your business is looking for mitigation of certain tax exposures, identification and capture of tax attributes and planning opportunities, assistance with structuring contractual protections, or tax efficient rollovers of executives’ equity, we’re here for you.
Our approach is tailored to address each client’s goals, minimizing risk and maximizing deal economics. Contact our team today.
RELATED INSIGHTS
We provide end-to-end support from strategy to execution to drive value at every stage of your merger, acquisition or divestiture.
Compensation & Benefits: The best way to retain top talent during a merger or acquisition is to get in front of the new compensation plan early.
We help clients solve complex tax issues once the merger or acquisition deal has been made.
Digital Deception: Fighting Fraud in the Era of Emerging Technology
August 26, 2025
Davin Teo and Henry Chambers, Managing Directors and Co-leaders of Disputes and Investigations Asia wrote an article on digital deception for the Hong Kong Chartered Governance Institute’s CGj August 2025 issue.
Unlocking Federal Real Estate: Efficiency, Partnerships, and the Path Ahead
August 26, 2025
Managing Director Tom Scott and Senior Director Paul Firth, join George Guszcza, President & CEO of the National Institute of Building Sciences, on The GovNavigators Show to discuss trends, challenges, and opportunities shaping the future of federal real estate.
DOJ and HHS collaborate to enhance False Claims Act prosecution
August 25, 2025
In a recent article for Westlaw Today, Managing Directors Jenelle Beavers and Donald Lochabay explore the U.S. government’s new collaboration and enforcement priorities around the False Claims Act (FCA).
Next-Generation Antibodies: A New Era in Immuno-Oncology
August 25, 2025
As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes, broadening coverage, and overcoming resistance mechanisms.
